BCWORLD PHARM. Co (200780) Fair Value & Analysis
Healthcare · KR · Market cap 32.8B KRW
Fair value as of: Jul 22, 2026
From 13 valuation models · updated 19 days ago
Share price +0.3% over the past month.
Below-average quality, and screening another 43% overvalued on our models.
What matters now
- Weak quality (34/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The model range is unusually wide (926.23 KRW to 3,297 KRW). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.
How to read this chart
60‑month range 2,960 KRW – 17,121 KRW · fair‑value band 926.23 KRW – 3,297 KRW · the 3,215 KRW price screens above the 1,822 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 22, 2026.
Analysis
BCWORLD PHARM. Co (200780) currently trades at 3,215 KRW, while our model-based Fair Value estimate is 1,822 KRW, implying the stock looks roughly 43.3% overvalued today. The Quality Score stands at 34/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, BCWORLD PHARM. Co generated revenue of 49.3B KRW at a net margin of 15.2%. Revenue grew 25.4% year over year. It earns a return on equity of 9.8%. Net debt stands at 80.4B KRW. Fundamentals as of Jul 22, 2026
Our scenario range runs from 926.23 KRW (bear case) to 3,297 KRW (bull case); at 3,215 KRW, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 47% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -25% fair-value upside, at -43%, 200780 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 13 models by family
Widest divergence: Asset-Based (4,673 KRW) versus Earnings-Based (1,159 KRW). Highest evidence: Growth DCF (80).
Notify me when 200780 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 29 · Market factors (momentum, volatility) 27
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
BCWORLD PHARM. Co., Ltd. operates as a pharmaceutical company in South Korea. The company provides products in various therapeutic areas comprising musculoskeletal system, digestive system, circulatory machine, central nervous system, adrenocorticosteroids, narcotic analgesics, erectile dysfunction treatment, wellbeing injection, diuretic, antitussive …
Full company description
BCWORLD PHARM. Co., Ltd. operates as a pharmaceutical company in South Korea. The company provides products in various therapeutic areas comprising musculoskeletal system, digestive system, circulatory machine, central nervous system, adrenocorticosteroids, narcotic analgesics, erectile dysfunction treatment, wellbeing injection, diuretic, antitussive expectorant, vaginitis treatment, anti-tuberculosis drugs, anti-emetic, antiviral drugs, antibiotic, anti-malignant tumor drugs, antifungal agent, antihistamines, antidote, and antipyretic/analgesic/anti-inflammatory. BCWORLD PHARM. Co., Ltd. was founded in 1980 and is headquartered in Seongnam-si, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
BCWORLD PHARM. Co reported revenue of 75.8B KRW in FY2025 versus 62.1B KRW in FY2021, a compound +5.1%/yr. Reported net income was −4.9B KRW in FY2025.
200780 screens 43% overvalued. Compare with Eli Lilly and Company →
Peer Group
Drug Manufacturers - General · 76 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - General median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,182 | $396.77 | -66% |
| Johnson & Johnson, JNJ | $257.59 | $169.04 | -34% |
| AbbVie Inc ABBV | $254.49 | $67.72 | -73% |
| Roche Holding 1RO | €392.80 | €226.68 | -42% |
| Merck & Co MRK | €108.08 | €121.54 | +12% |
| Novartis AG NVSN | 2,742 MXN | 2,379 MXN | -13% |
| AstraZeneca PLC AZN | $171.61 | $129.54 | -25% |
| Novo Nordisk A/S NOVOB | kr 329.90 | kr 409.46 | +24% |
| Amgen Inc AMGN | $363.39 | $252.02 | -31% |
| Sanofi SNYN | 770.00 MXN | 1,251 MXN | +63% |
Compare BCWORLD PHARM. Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is BCWORLD PHARM. Co (200780) overvalued or undervalued?
What is the fair value of 200780?
What is the quality score of 200780?
What is the revenue of BCWORLD PHARM. Co (200780)?
What is the net profit margin of 200780?
Does BCWORLD PHARM. Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track BCWORLD PHARM. Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.